Biomarker Discovery Services
Precision medicine meets real-time breath analysis
Breath Analysis: The Next Frontier
Volatile Organic Compounds (VOCs) are gaseous molecules generated as by-products of the body's metabolic activities. With over 1,000 VOCs present in every breath, their accurate interpretation offers a robust and comprehensive assessment of the body's health status. Through the pioneering efforts of scientific and academic institutions worldwide, the utilisation of breath analysis in healthcare has evolved from a promising concept to a validated scientific method, posing to coexist with traditional blood, saliva, and urine analyses in the near future.
Today, the question is not whether breath analysis is a reliable method, but rather which technology is most suitable to meet our healthcare standards, and which diseases and applications to prioritize.
Exhalon.io: built on the world's most advanced real-time gas analytics technology, powered by AI
Services
From inception to completion, we cover every step of the biomarker discovery process.
Clinical Trial Planification
Biomarker Discovery
Assay Development & Validation
Applications
Diagnostics:
Like with our first found success in COVID-19, real-time breath analysis is a proven technique for non-invasive, immediate, and highly accurate diagnostics.
Patient monitoring:
By enabling continuous monitoring of breath profiles, we can offer immediate insights into changes in health status. Detecting fluctuations in Volatile Organic Compounds (VOCs) in real-time facilitates proactive interventions and personalized treatment adjustments for patients.
Prognostics:
Breath analysis has demonstrated remarkable accuracy in predicting the progression of numerous medical conditions. To further the proof, we are currently investigating its application in prevalent respiratory diseases such as COPD and asthma, aiming to forecast the probability of patients' suffering from exacerbations based on their breath profile. Such predictive insights could revolutionize respiratory care.
Therapy response prediction:
Certain VOCs are inherently unique to each individual, or group of individuals, allowing us to correlate specific VOC patterns with particular therapy responses. By analysing these patterns, we can stratify patients based on their likelihood of responding to a given therapy, enabling caregivers to tailor treatments accordingly. This application holds great promise for the development of novel precision drugs. Our recent studies have yielded highly encouraging results in our capacity of predicting the response of patients to a novel precision drug for the treatment of Cystic Fibrosis.
Team
José A. López Montemayor, MBA
CEO, co-founder
Prof. Stanislas Grassin-Delyle
CMO & CSO, co-founder
Board
